A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm
Cancer · 15.09.2023 · 129 (18) · 2773-2788
DOI: 10.1002/cncr.34904 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 22.06.2023. Verfasst von Arya Mariam Roy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Antineoplastic Agents, Immunoconjugates. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
The expansion of the spectrum of human epidermal growth factor receptor 2 (HER2)‐status to HER2‐low, defined as HER2 expression of 1+ by immunohistochemistry (IHC) or 2+ by IHC without gene amplification, has made a major impact in the field of oncology. The HER2‐low expression has emerged as a targetable biomarker, and anti‐HER2 antibody‐drug conjugate trastuzumab deruxtecan has shown significant survival benefit in pretreated metastatic HER2‐low breast cancer (BC). With these recent data, the treatment algorithm for hormone receptor–positive and triple‐negative BC needs to be reconsidered, as approximately half of these BCs are HER2‐low. Although there are different therapeutic agents for hormone receptor–positive and hormone receptor–negative HER2‐low BCs, there is no consensus regarding the sequencing of these agents. In this article, the treatment options for HER2‐low BC are enumerated and a treatment sequencing algorithm based on the current clinical evidence proposed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
- Department of Medicine, University at Buffalo, Buffalo, New York, USA.
- Department of Medicine, University of Rochester Medical Center, Rochester, New York, USA.
ORCID-Profile: Arya Mariam Roy, Ajay Dhakal, Ruth O'Regan, Shipra Gandhi
Förderung
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
Zitieren
APA
Roy, A. M., Kumarasamy, V. M., Dhakal, A., O'Regan, R., & Gandhi, S. (2023). A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm. Cancer, 129(18), 2773-2788. https://doi.org/10.1002/cncr.34904
Vancouver
Roy AM, Kumarasamy VM, Dhakal A, O'Regan R, Gandhi S. A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm. Cancer. 2023;129(18):2773-2788. doi:10.1002/cncr.34904
BibTeX
@article{Roy2023,
author = {Roy, Arya Mariam and Kumarasamy, Vasanthan Muthusamy and Dhakal, Ajay and O'Regan, Ruth and Gandhi, Shipra},
title = {A review of treatment options in HER2‐low breast cancer and proposed treatment sequencing algorithm},
journal = {Cancer},
year = {2023},
volume = {129},
number = {18},
pages = {2773--2788},
doi = {10.1002/cncr.34904}
}
EUVIMED